Sanofi-Aventis reports PhIII success for diabetes drug

Sanofi-Aventis has gained some fresh evidence to back lixisenatide, its late-stage GLP-1 therapy for Type 2 diabetes. Researchers say that the drug improved glycemic control in patients and reduced glucose in blood cells, making its Phase III study a success. The therapy was licensed from Zealand Pharma.

"We are pleased with the top-line results from our first Phase III study of this novel, once-daily GLP-1 agonist and are looking forward to sharing the full results later in the year," said Marc Cluzel, Sanofi's executive vice-president for research and development. The 12-week study enrolled 361 volunteers.

The good news was tempered by some considerable caution among analysts who have begun to fret over the number of GLP-1 drugs being advanced by competitors like Eli Lilly and Novo Nordisk.

"We currently assume peak sales of $500 million (for lixisenatide) with a 2012 launch but see the drug as being a late-comer in what is looking to be a crowded GLP-1 market," noted Jefferies International.

- see the release on lixisenatide
- here's the story from Reuters

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.